Similar articles

• Fatal bacteraemia caused by daptomycin-non-susceptible, vancomycin-intermediate, meticillin-resistant Staphylococcus aureus in a patient with chronic kidney disease.

  Kuo CC, Wu VC, Huang YT, Liao CH, Hsueh PR. Kuo CC, et al. Int J Antimicrob Agents. 2009 Jan;33(1):96-8. doi: 10.1016/j.ijantimicag.2008.06.028. Epub 2008 Sep 13. Int J Antimicrob Agents. 2009. PMID: 18790610 No abstract available.
• Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia.

  Jacobson LM, Milstone AM, Zenilman J, Carroll KC, Arav-Boger R. Jacobson LM, et al. Pediatr Infect Dis J. 2009 May;28(5):445-7. doi: 10.1097/INF.0b013e3181927891. Pediatr Infect Dis J. 2009. PMID: 19295462
• Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.

  Bennett JW, Murray CK, Holmes RL, Patterson JE, Jorgensen JH. Bennett JW, et al. Diagn Microbiol Infect Dis. 2008 Apr;60(4):437-40. doi: 10.1016/j.diagmicrobio.2007.11.002. Epub 2007 Dec 21. Diagn Microbiol Infect Dis. 2008. PMID: 18096352
• Review: Daptomycin for the treatment of gram-positive infections in neutropenic cancer patients.

  Rolston KV. Rolston KV. Clin Adv Hematol Oncol. 2008 Nov;6(11):815-7. Clin Adv Hematol Oncol. 2008. PMID: 19194365 Review. No abstract available.
• Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.

  Nannini E, Murray BE, Arias CA. Nannini E, et al. Curr Opin Pharmacol. 2010 Oct;10(5):516-21. doi: 10.1016/j.coph.2010.06.006. Epub 2010 Jul 1. Curr Opin Pharmacol. 2010. PMID: 20598637 Review.